...
首页> 外文期刊>BMC Gastroenterology >Ozagrel hydrochloride, a selective thromboxane A2 synthase inhibitor, alleviates liver injury induced by acetaminophen overdose in mice
【24h】

Ozagrel hydrochloride, a selective thromboxane A2 synthase inhibitor, alleviates liver injury induced by acetaminophen overdose in mice

机译:盐酸奥扎格雷,一种选择性血栓烷A2合酶抑制剂,减轻了对乙酰氨基酚过量引起的小鼠肝损伤

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Background Overdosed acetaminophen (paracetamol, N-acetyl-p-aminophenol; APAP) causes severe liver injury. We examined the effects of ozagrel, a selective thromboxane A2 (TXA2) synthase inhibitor, on liver injury induced by APAP overdose in mice. Methods Hepatotoxicity was induced to ICR male mice by an intraperitoneal injection with APAP (330 mg/kg). The effects of ozagrel (200 mg/kg) treatment 30 min after the APAP injection were evaluated with mortality, serum alanine aminotransferase (ALT) levels and hepatic changes, including histopathology, DNA fragmentation, mRNA expression and total glutathione contents. The impact of ozagrel (0.001-1 mg/mL) on cytochrome P450 2E1 (CYP2E1) activity in mouse hepatic microsome was examined. RLC-16 cells, a rat hepatocytes cell line, were exposed to 0.25 mM N-acetyl-p-benzoquinone imine (NAPQI), a hepatotoxic metabolite of APAP. In this model, the cytoprotective effects of ozagrel (1–100 muM) were evaluated by the WST-1 cell viability assay. Results Ozagel treatment significantly attenuated higher mortality, elevated serum alanine aminotransferase levels, excessive hepatic centrilobular necrosis, hemorrhaging and DNA fragmentation, as well as increase in plasma 2,3-dinor thromboxane B2 levels induced by APAP injection. Ozagrel also inhibited the hepatic expression of cell death-related mRNAs induced by APAP, such as jun oncogene, FBJ osteosarcoma oncogene (fos) and C/EBP homologous protein (chop), but did not suppress B-cell lymphoma 2-like protein11 (bim) expression and hepatic total glutathione depletion. These results show ozagrel can inhibit not all hepatic changes but can reduce the hepatic necrosis. Ozagrel had little impact on CYP2E1 activity involving the NAPQI production. In addition, ozagrel significantly attenuated cell injury induced by NAPQI in RLC-16. Conclusions We demonstrate that the TXA2 synthase inhibitor, ozagrel, dramatically alleviates liver injury induced by APAP in mice, and suggest that it is a promising therapeutic candidate for the treatment of APAP-induced liver injury.
机译:背景过量对乙酰氨基酚(扑热息痛,N-乙酰基-对氨基苯酚; APAP)会导致严重的肝损伤。我们研究了ozagrel(一种选择性血栓烷A 2 (TXA 2 )合酶抑制剂)对过量APAP引起的小鼠肝损伤的影响。方法腹腔注射APAP(330 mg / kg)对ICR雄性小鼠有肝毒性作用。通过死亡率,血清丙氨酸氨基转移酶(ALT)水平和肝脏变化(包括组织病理学,DNA片段化,mRNA表达和总谷胱甘肽含量)评估奥扎格雷(200 mg / kg)处理APAP后30分钟的效果。检查了奥扎格雷(0.001-1 mg / mL)对小鼠肝微粒体中细胞色素P450 2E1(CYP2E1)活性的影响。将RLC-16细胞(一种大鼠肝细胞细胞系)暴露于0.25 mM N-乙酰基-对-苯醌亚胺(NAPQI)(APAP的肝毒性代谢产物)中。在该模型中,通过WST-1细胞活力分析评估了奥扎格雷(1–100μM)的细胞保护作用。结果Ozagel治疗显着降低了APAP注射所致的更高死亡率,血清丙氨酸氨基转移酶水平升高,肝小叶坏死过多,出血和DNA片段化以及血浆2,3-二价血栓烷B 2 升高。奥扎格雷还抑制由APAP诱导的肝细胞死亡相关mRNA的表达,例如jun癌基因,FBJ骨肉瘤癌基因(fos)和C / EBP同源蛋白(chop),但不抑制B细胞淋巴瘤2样蛋白11( bim)表达和肝脏总谷胱甘肽耗竭。这些结果表明,奥扎格雷不能抑制所有的肝改变,但可以减少肝坏死。奥扎格雷对涉及NAPQI产生的CYP2E1活性影响很小。此外,奥扎格雷显着减轻了NLCQI在RLC-16中诱导的细胞损伤。结论我们证明TXA 2 合酶抑制剂ozagrel可以显着减轻APAP诱导的小鼠肝损伤,并表明它是治疗APAP诱导的肝损伤的有希望的治疗候选物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号